Conclusions
VTE
SECONDARY
This secondary analysis of a cluster randomized crossover clinical trial found that among patients undergoing hip or knee arthroplasty, there was no difference in mortality within 90 days between patients allocated to enoxaparin vs aspirin used for VTE prophylaxis. In conjunction with the results from the primary CRISTAL study,